DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PROSPECTIVE PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF PANZYGA IN PRIMARY INFECTION PROPHYLAXIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA ("PRO-SID" study)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Octapharma AG
Start Date
November 20, 2020
End Date
December 13, 2023
Administered By
Duke Cancer Institute
Awarded By
Octapharma AG
Start Date
November 20, 2020
End Date
December 13, 2023